{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:44:41Z","timestamp":1792154681386,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.encep.2026.06.015","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:47:14Z","timestamp":1792151234000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["French psychiatric caregivers\u2019 perceptions of psychedelics: A national survey"],"prefix":"10.1016","author":[{"given":"Anne","family":"Buot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-6324","authenticated-orcid":false,"given":"Jean-Del","family":"Burdairon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Berkovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2026.06.015_bib0210","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.encep.2026.06.015_bib0215","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.encep.2026.06.015_bib0220","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs. placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0225","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2026.06.015_bib0230","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0240","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"key":"10.1016\/j.encep.2026.06.015_bib0245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0250","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.encep.2026.06.015_bib0255","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2026.06.015_bib0260","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2025.13481","article-title":"Single treatment with MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial","volume":"334","author":"Robison","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.encep.2026.06.015_bib0265","doi-asserted-by":"crossref","first-page":"103149","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","volume":"82","author":"Rieser","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.encep.2026.06.015_bib0270","doi-asserted-by":"crossref","DOI":"10.1111\/add.70152","article-title":"Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial","author":"Luquiens","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.encep.2026.06.015_bib0275","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2026.06.015_bib0280","doi-asserted-by":"crossref","first-page":"e260972","DOI":"10.1001\/jamanetworkopen.2026.0972","article-title":"Psilocybin or nicotine patch for smoking cessation: a pilot randomized clinical trial","volume":"9","author":"Johnson","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.encep.2026.06.015_bib0285","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.genhosppsych.2025.08.001","article-title":"Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: a phase 2b randomized controlled trial","volume":"96","author":"Ross","year":"2025","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0290","first-page":"247","article-title":"Psilocybin for treatment of obsessive compulsive disorder","volume":"56","author":"Moreno","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.encep.2026.06.015_bib0295","doi-asserted-by":"crossref","first-page":"152619","DOI":"10.1016\/j.comppsych.2025.152619","article-title":"Single-dose (10\u00a0mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: a pharmacological challenge study","volume":"142","author":"Pellegrini","year":"2025","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0300","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.289.15.1969","article-title":"Disseminating innovations in health care","volume":"289","author":"Berwick","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.encep.2026.06.015_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2024.2424263","article-title":"Does the perception of risk associated with psychedelics use differ in physicians according to their belief of effectiveness?","volume":"58","author":"Bezo","year":"2026","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.encep.2026.06.015_bib0310","series-title":"Les parcours dans l\u2019organisation des soins de psychiatrie","author":"Cour des comptes","year":"2021"},{"key":"10.1016\/j.encep.2026.06.015_bib0315","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1176\/appi.ajp.20240644","article-title":"Ketamine, the first associative anesthetic? Some considerations on classifying psychedelics, entactogens, and dissociatives","volume":"181","author":"Denomme","year":"2024","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0320","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00023210-200620030-00003","article-title":"Ketamine: from medicine to misuse","volume":"20","author":"Wolff","year":"2006","journal-title":"CNS Drug"},{"key":"10.1016\/j.encep.2026.06.015_bib0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov Ment Health"},{"key":"10.1016\/j.encep.2026.06.015_bib0330","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.encep.2026.06.015_bib0335","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.encep.2026.06.015_bib0340","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-024-01622-3","article-title":"MDMA therapy for PTSD rejected by FDA panel","author":"Reardon","year":"2024","journal-title":"New Nature"},{"key":"10.1016\/j.encep.2026.06.015_bib0345","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cpp.2880","article-title":"Psychologists\u2019 and psychotherapists\u2019 knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics","volume":"30","author":"Kucsera","year":"2023","journal-title":"Clin Psychol Psychother"},{"key":"10.1016\/j.encep.2026.06.015_bib0350","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/NMD.0000000000000828","article-title":"A survey of American psychiatrists\u2019 attitudes toward classic hallucinogens","volume":"206","author":"Barnett","year":"2018","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.encep.2026.06.015_bib0355","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/02791072.2021.1957183","article-title":"Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey","volume":"54","author":"Barnett","year":"2022","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.encep.2026.06.015_bib0360","doi-asserted-by":"crossref","first-page":"28022","DOI":"10.1038\/s41598-024-78736-1","article-title":"Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.encep.2026.06.015_bib0365","doi-asserted-by":"crossref","first-page":"1190507","DOI":"10.3389\/fpsyt.2023.1190507","article-title":"Medical student attitudes and perceptions of psychedelic-assisted therapies","volume":"14","author":"Li","year":"2023","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.encep.2026.06.015_bib0370","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ajad.13461","article-title":"Addiction specialists\u2019 attitudes toward psychedelics: a National Survey","volume":"32","author":"Kim","year":"2023","journal-title":"Am J Addict"},{"key":"10.1016\/j.encep.2026.06.015_bib0375","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/09687637.2022.2117022","article-title":"Predictors of attitudes toward psychedelics among psychologists in the USA","volume":"30","author":"Luoma","year":"2023","journal-title":"Drugs Educ Prev Policy"},{"key":"10.1016\/j.encep.2026.06.015_bib0380","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/02791072.2021.1971343","article-title":"Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States","volume":"54","author":"Davis","year":"2022","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.encep.2026.06.015_bib0385","doi-asserted-by":"crossref","first-page":"114727","DOI":"10.1016\/j.psychres.2022.114727","article-title":"Magic Mushrooms\u00a0\u2013\u00a0an exploratory look at how mental health professionals feel and think about Psilocybin","volume":"316","author":"Meyer","year":"2022","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.encep.2026.06.015_bib0390","doi-asserted-by":"crossref","first-page":"103816","DOI":"10.1016\/j.drugpo.2022.103816","article-title":"Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States","volume":"108","author":"Levin","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.encep.2026.06.015_bib0395","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1556\/2054.2023.00294","article-title":"Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: a systematic review","volume":"8","author":"Wells","year":"2024","journal-title":"J Psychedelic Stud"},{"key":"10.1016\/j.encep.2026.06.015_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2024.2424263","article-title":"Does the perception of risk associated with psychedelics use differ in physicians according to their belief of effectiveness?","volume":"58","author":"Bezo","year":"2024","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.encep.2026.06.015_bib0405","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.encep.2023.11.008","article-title":"Opinions of French psychiatrists on the regulatory status of cannabis: results from the \u201cPsyCan\u00a0\u2013\u00a0Enc\u00e9phale\u201d national online survey","volume":"50","author":"Leclerc","year":"2024","journal-title":"L\u2019Enc\u00e9phale"},{"key":"10.1016\/j.encep.2026.06.015_bib0410","first-page":"1","article-title":"Les niveaux d\u2019usage des drogues illicites en France en 2023","volume":"164","author":"Spilka","year":"2024","journal-title":"Tendances"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700626001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700626001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:47:18Z","timestamp":1792151238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700626001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S0013700626001867"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2026.06.015","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French psychiatric caregivers\u2019 perceptions of psychedelics: A national survey","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2026.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}